Experimental myeloma drug tasquinimod tested in early trial – but study halted

NCT ID NCT04405167

Terminated Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new drug called tasquinimod, alone or with standard chemotherapy, in 30 adults with multiple myeloma that had relapsed or become resistant. The main goal was to find a safe dose and check for side effects. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tasquinimod (oral capsules), sometimes combined with ixazomib, lenalidomide, and dexamethasone
What this could lead to: If successful, this could point toward a new treatment option for people with multiple myeloma that has come back or not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 30 participants, now terminated. It was designed mainly to find a safe dose, not to prove effectiveness. The drug may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.